Uppsala, Sweden – April 20, 2018 – As previously communicated Orexo will announce the Interim Report for Q1 2018 on Thursday, April 26 at 8.00 am CET. The same day at 3.00 pm CET, analysts, investors and media are invited to attend an audiocast with a web presentation where CEO, Nikolaj Sørensen, and CFO, Henrik Juuel, will present the report. After the presentation a Q&A will be held. Questions can also be sent in advance to firstname.lastname@example.org, no later than 11.00 am CET.
Please view the instructions below on how to participate.
Telephone: (SE) +46 856 642 664, (UK) + 44 203 008 9802 or (US) + 18 557 532 235.
The presentation material will be available on Orexo´s website one hour prior to the audiocast.
For further information, please contact:
Orexo AB (publ.)
Lena Wange, IR & Communications Manager
Tel: +46 (0)18 780 88 00
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The products are commercialized by Orexo in the US or via selected partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product Zubsolv®. Total net sales for 2017 amounted to SEK 643.7 million and the number of employees at year-end was 90. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube. For more information about Zubsolv in the US, see the product and market websites www.zubsolv.com and www.rise-us.com.